Preparation, characterization, and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model.
暂无分享,去创建一个
Hazem Ali | E. Rytting | Erik Rytting | Irina Kalashnikova | Mark Andrew White | Michael Sherman | I. Kalashnikova | H. Ali | M. A. White | M. Sherman
[1] Claudia J. Bode,et al. In vitro models for studying trophoblast transcellular transport. , 2006, Methods in molecular medicine.
[2] Xiaoying Wang,et al. Preparation of nanoparticles by solvent displacement for drug delivery: a shift in the "ouzo region" upon drug loading. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[3] Ziyaur Rahman,et al. Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design. , 2010, International journal of pharmaceutics.
[4] Michael J. Campolongo,et al. Drug delivery: Old polymer learns new tracts. , 2009, Nature materials.
[5] Zhirong Zhang,et al. Lung-targeting delivery of dexamethasone acetate loaded solid lipid nanoparticles , 2007, Archives of pharmacal research.
[6] Elias Fattal,et al. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. , 2007, International journal of pharmaceutics.
[7] David C. Martin,et al. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. , 2006, Biomaterials.
[8] Yasuo Yoshioka,et al. Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. , 2011, Nature nanotechnology.
[9] Karsten Mäder,et al. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[10] M. New,et al. Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia. , 2011, Pediatric clinics of North America.
[11] Steven J Siegel,et al. Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. , 2008, International journal of pharmaceutics.
[12] P. Sylvester,et al. Preparation and in vitro antiproliferative effect of tocotrienol loaded lipid nanoparticles , 2010 .
[13] M. Ferrari,et al. Size of the nanovectors determines the transplacental passage in pregnancy: study in rats. , 2011, American journal of obstetrics and gynecology.
[14] S. Weaver,et al. Structure of the Recombinant Alphavirus Western Equine Encephalitis Virus Revealed by Cryoelectron Microscopy , 2010, Journal of Virology.
[15] H. Fessi,et al. Physicochemical Parameters Associated with Nanoparticle Formation in the Salting-Out, Emulsification-Diffusion, and Nanoprecipitation Methods , 2004, Pharmaceutical Research.
[16] Thomas J. Raub,et al. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. , 1989, Gastroenterology.
[17] Robert Langer,et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. , 2009, Biomaterials.
[18] W. Mark Saltzman,et al. Nanotechnology for delivery of drugs to the brain for epilepsy , 2009, Neurotherapeutics.
[19] Hanne Mørck Nielsen,et al. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[20] M. New. An Update of Congenital Adrenal Hyperplasia , 2004, Annals of the New York Academy of Sciences.
[21] Michael Tseng,et al. Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[22] H. Okada,et al. Controlled Release of LHRH Agonist, Leuprolide Acetate, from Microcapsules: Serum Drug Level Profiles and Pharmacological Effects in Animals , 1989, The Journal of pharmacy and pharmacology.
[23] Jayanth Panyam,et al. Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. , 2004, Journal of pharmaceutical sciences.
[24] F P Booy,et al. Electron microscopy of frozen biological suspensions , 1983, Journal of microscopy.
[25] C. Weiner,et al. 9a Medical fetal therapy , 1995 .
[26] J. Rinehart,et al. Nanoparticles Containing Anti-inflammatory Agents as Chemotherapy Adjuvants: Optimization and In Vitro Characterization , 2008, The AAPS Journal.
[27] S. Nimkarn,et al. Congenital adrenal hyperplasia due to 21‐hydroxylase deficiency , 2010, Annals of the New York Academy of Sciences.
[28] H. M. Nielsen,et al. In vitro placental model optimization for nanoparticle transport studies , 2012, International journal of nanomedicine.
[29] K. Audus,et al. Transport and metabolism of opioid peptides across BeWo cells, an in vitro model of the placental barrier. , 2002, International journal of pharmaceutics.
[30] S. Schwendeman,et al. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[31] A. R. Kulkarni,et al. Biodegradable polymeric nanoparticles as drug delivery devices. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[32] Claus-Michael Lehr,et al. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. , 2007, Nanomedicine : nanotechnology, biology, and medicine.
[33] J. Kreuter. Drug targeting with nanoparticles , 1994, European Journal of Drug Metabolism and Pharmacokinetics.
[34] H. Okada,et al. One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. , 1997, Advanced drug delivery reviews.
[35] J. Zelikoff,et al. Cadmium associated with inhaled cadmium oxide nanoparticles impacts fetal and neonatal development and growth. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.
[36] H. Bruinse,et al. Congenital Adrenal Hyperplasia: Do the Benefits of Prenatal Treatment Defeat the Risks? , 2010, Obstetrical & gynecological survey.
[37] Jesper B Nielsen,et al. Placental transport and in vitro effects of Bisphenol A. , 2010, Reproductive toxicology.
[38] P. Myllynen,et al. Kinetics of gold nanoparticles in the human placenta. , 2008, Reproductive toxicology.
[39] E. Ritzén. Prenatal dexamethasone treatment of fetuses at risk for congenital adrenal hyperplasia: benefits and concerns. , 2001, Seminars in neonatology : SN.
[40] M. New,et al. Prenatal diagnosis and treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency , 2009, Molecular and Cellular Endocrinology.
[41] R. Kannan,et al. Transfer of PAMAM dendrimers across human placenta: prospects of its use as drug carrier during pregnancy. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[42] M. New,et al. EXTENSIVE PERSONAL EXPERIENCE: Prenatal Diagnosis for Congenital Adrenal Hyperplasia in 532 Pregnancies , 2001 .
[43] Dae-Duk Kim,et al. Enhancing effect of surfactants on fexofenadine.HCl transport across the human nasal epithelial cell monolayer. , 2007, International journal of pharmaceutics.
[44] A. Welle,et al. PLGA:poloxamer blend micro- and nanoparticles as controlled release systems for synthetic proangiogenic factors. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[45] Xiangrong Song,et al. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[46] Peter Wick,et al. Barrier Capacity of Human Placenta for Nanosized Materials , 2009, Environmental health perspectives.
[47] Xiangrong Song,et al. PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. , 2008, International journal of pharmaceutics.
[48] V. Montori,et al. Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia because of 21‐hydroxylase (CYP21A2) deficiency: a systematic review and meta‐analyses , 2010, Clinical endocrinology.
[49] A. Ludwig,et al. Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. , 2006, International journal of pharmaceutics.
[50] N. Zhang,et al. Studies on bioadhesive PLGA nanoparticles: A promising gene delivery system for efficient gene therapy to lung cancer. , 2009, International journal of pharmaceutics.
[51] L. Knudsen,et al. Modeling placental transport: correlation of in vitro BeWo cell permeability and ex vivo human placental perfusion. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.
[52] R. A. Jain,et al. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. , 2000, Biomaterials.
[53] K. Audus,et al. Low-affinity uptake of the fluorescent organic cation 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (4-Di-1-ASP) in BeWo cells. , 2007, Biochemical pharmacology.